aortic stenosis

implante de la valvula aortica transcateter

TAVR Reaches Low-Risk Patients with Bicuspid Valves

Transcatheter aortic valve replacement (TAVR) seems to be safe in low-risk patients with bicuspid aortic valve stenosis. Their hospital length of stay was very short, with zero mortality, and zero disabling stroke. Subclinical leaflet thrombosis and device durability are still unknown. The United States Food and Drug Administration (FDA) approved TAVR for low-risk patients. However,<a href="https://solaci.org/en/2020/04/27/tavr-reaches-low-risk-patients-with-bicuspid-valves/" title="Read more" >...</a>

Recomendaciones de la ACC con el nuevo coronavirus

Procedural Rescheduling Criteria in the Pandemic Era

Patients with structural heart disease are at higher risk in the face of the new coronavirus infection due to both advanced age and numerous comorbidities. All variables must be taken into account when deciding whether a patient can wait (so as to minimize the risk of exposure to the virus) or their pathology must be<a href="https://solaci.org/en/2020/04/20/procedural-rescheduling-criteria-in-the-pandemic-era/" title="Read more" >...</a>

Predilatación en TAVI ¿Datos definitivos para no complicarse tomando decisiones?

Predilation in TAVR: Definitive Data for Easier Decision-Making?

Direct implantation (without predilation) resulted non-inferior vs. the conventional strategy with prior balloon aortic valvuloplasty using the S3 prosthesis (even though this did not translate into a simplified procedure). In a few patients, the prosthesis was not able to cross the native valve, which resulted in device retrieval and subsequent valvuloplasty. According to these data,<a href="https://solaci.org/en/2020/04/07/predilation-in-tavr-definitive-data-for-easier-decision-making/" title="Read more" >...</a>

Virtual ACC 2020 | First Results of Evolut in Low-Risk Bicuspid Valves

The initial results of this study presented “virtually” at the American College of Cardiology (ACC) 2020 Scientific Session suggest that patients with severe bicuspid aortic stenosis can be treated with self-expandable valve Evolut. This is a small study presenting its 30-day outcomes. There is still a long way to go. The rate of all-cause mortality<a href="https://solaci.org/en/2020/04/02/virtual-acc-2020-first-results-of-evolut-in-low-risk-bicuspid-valves/" title="Read more" >...</a>

ACC 2020 Virtual | PARTNER 3: TAVI vs cirugía en bajo riesgo a 2 años de seguimiento

Virtual ACC 2020 | PARTNER 3: TAVR vs CABG in Low Risk at 2 Years

The 2-year outcomes in patients with severe aortic stenosis and low surgical risk continue to show a numerical benefit in favor of transcatheter aortic valve replacement (TAVR) vs. surgical replacement (CABG) for the primary end point of death, stroke or repeat hospitalization for cardiovascular reasons. However, the initially higher advantage of TAVR has been narrowing<a href="https://solaci.org/en/2020/04/02/virtual-acc-2020-partner-3-tavr-vs-cabg-in-low-risk-at-2-years/" title="Read more" >...</a>

tavi calcificación del anillo mitral

TAVR in Small Annuli: Is There a Better Valve?

Transcatheter aortic valve replacement with the self-expandable valves has shown optimal clinical and electrocardiographic results in patients with small annuli. These supra-annular prosthetic valves seem somewhat better than the intra-annular balloon expandable.&nbsp; TAVR in general has better functional results in terms of patient/prosthesis mismatch. This seems especially true for patients with a small annulus.&nbsp; The<a href="https://solaci.org/en/2020/03/20/tavr-in-small-annuli-is-there-a-better-valve/" title="Read more" >...</a>

acceso_transcaval

Europe Advances the Transcaval Approach for TAVR

The transfemoral access is clearly the preferred approach to transcatheter aortic valve replacement (TAVR), followed by the trans-axillary or trans-subclavian. Despite the alternatives, some patients are still ineligible. This study recently published in EuroIntervention reports initial experiences in Europe with the transfemoral transcaval approach.&nbsp; It included 50 patients from 5 centers assessed according to the<a href="https://solaci.org/en/2020/03/17/europe-advances-the-transcaval-approach-for-tavr/" title="Read more" >...</a>

mas-leido-noviembre-eng

The Most Read Articles of November at Solaci.org

1- AHA 2019 | ISCHEMIA: The Invasive Approach (PCI or Surgery) Results Similar to Optimal Medical Treatment After a several year follow up, the International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) has shown that an invasive approach in addition to optimal medical treatment (OMT) does not offer benefits when it<a href="https://solaci.org/en/2019/12/02/the-most-read-articles-of-november-at-solaci-org/" title="Read more" >...</a>

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

Pre-TAVR Revascularization: Angiographic or Physiological?

In patients undergoing transcatheter aortic valve replacement (TAVR), fractional flow reserve (FFR) guided revascularization is associated with favorable results compared against the traditional angiography guided revascularization.&nbsp; Given the complete lack of randomized studies, this observational study is the best we have to decide how to guide revascularization in patients with symptomatic severe aortic stenosis undergoing<a href="https://solaci.org/en/2019/11/28/pre-tavr-revascularization-angiographic-or-physiological/" title="Read more" >...</a>

AHA 2019 | Sapien vs Evolut: A Head-to-Head Study Seems Mandatory

Two French registries have carried out a propensity matched comparison which suggest differences between balloon-expandable valves (BEV) and self-expandable valves (SEV) in hard end points such as mortality.&nbsp; The only FDA approved commercially available transcatheter heart valves in the US are the BE Sapien 3 (Edwards Lifesciences) and the SE CoreValve Evolut PRO (Medtronic). Both<a href="https://solaci.org/en/2019/11/27/aha-2019-sapien-vs-evolut-a-head-to-head-study-seems-mandatory/" title="Read more" >...</a>

Top